Ep 28 | From Google Glass to AI Scribes: The Augmedix Journey | Ian Shakil | Founder, Director, Chief Strategy Officer of Augmedix

Below is the summary of the podcast episode featuring Ian Shakil from Augmedix, hosted by Drs Adam Carewe and Dale Gold:

Episode Summary

Ian Shakil, founder of Augmedix, discusses the evolution and impact of ambient scribing technology in healthcare, highlighting the company’s journey, innovations, and future directions. Additionally, recently announced Augmedix will be acquired by Commure, a large health tech company, to expand their capabilities and accelerate innovation in the ambient documentation space. This partnership aims to combine resources and offer a suite of solutions to healthcare systems, enhancing the overall efficiency and effectiveness of clinical documentation.

Section Summaries

* Introduction and Background: Ian Shakil shares his background and the founding story of Augmedix, emphasizing the inspiration behind creating ambient scribing technology to alleviate clinician burdens.

* Evolution of Technology: Ian explains the transition from using Google Glass to smartphones for ambient scribing, detailing the technological advancements and the shift from human-assisted to AI-driven documentation.

* Service Lines and Innovations: Augmedix offers three service lines: Augmedix Live (human-assisted), Augmedix Go (AI-driven), and Augmedix Go Assist (hybrid). Ian highlights the benefits and scalability of these services.

* Bidirectional Ambient Capabilities: Ian discusses the development of bidirectional ambient capabilities, which provide real-time guidance and reminders to clinicians, enhancing workflow and patient care.

* Challenges and Future Directions: The conversation covers the challenges of implementing ambient technology in chaotic environments like emergency departments and the potential future applications and innovations in the field.

Please share this post and episode with others

Get full access to Rewskidotcom by Adam Carewe MD at rewskidotcom.substack.com/subscribe